{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:13:23Z","timestamp":1783635203242,"version":"3.55.0"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"SBRI Healthcare\/NHSE England Cancer Programme Innovation Open Call - round 2","award":["NCPC02029"],"award-info":[{"award-number":["NCPC02029"]}]},{"name":"Wellbeing of Women Peaches - Womb Cancer Trust","award":["Postdoctoral Research Fellowship"],"award-info":[{"award-number":["Postdoctoral Research Fellowship"]}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the North Thames Mainstreaming of Breast Cancer Genetic Testing (NT-MBGT) programme, we piloted testing for breast cancer susceptibility genes (BCSGs) in unselected breast cancer (BC) patients, deploying a clinician-light \u2018BRCA-DIRECT\u2019 mainstreaming pathway; this included home saliva-testing and consent with postal return, written and digital materials, with full access to a Genetic Counsellor Telephone helpline. Across 14 National Health Service (NHS) breast oncology units, we successfully tested 3515 newly-diagnosed BC patients with high levels of patient and breast healthcare professional (HCP) satisfaction and genetics HCPs reporting decreases in service referrals. The pick-up rate of gPVs was 4.7% (166 germline Pathogenic Variants (gPVs) across seven BCSGs). Examining application of current NHS eligibility criteria to the unselected cohort, testing would have been offered to 20.6% of patients with identification of 49.2% of gPVs in high penetrance (HP)-BCSGs (BRCA1\/BRCA2\/PALB2) and 18.2% of gPVs in intermediate penetrance-BCSGs (CHEK2\/ATM\/RAD51C\/RAD51D). Designing \u2018Ultra-simple\u2019 eligibility criteria suitable for mainstreaming, detection (sensitivity) could be improved to 81.1% and 70.4% respectively, whilst increasing testing to 49.7% of BC cases. Evidence from the NT-MBGT programme demonstrates that expanding BCSG-testing via a clinician-light pathway is acceptable and feasible, without increasing the burden on limited breast and genetics workforce, and has high satisfaction.<\/jats:p>","DOI":"10.1038\/s41523-026-01000-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:14:20Z","timestamp":1783631660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Routine germline genetic testing in 3552 unselected NHS breast cancer patients: evidence informing testing criteria and implementation of a \u2018BRCA-DIRECT\u2019 mainstreaming pathway"],"prefix":"10.1038","author":[{"given":"Bethany","family":"Torr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin T.","family":"Fierheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hamill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeekshna","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"MacMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Clinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Valganon-Petrizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Legood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01000-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:14:20Z","timestamp":1783631660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01000-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":0,"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-01000-4","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.K. declares honoraria for educational resources (AstraZeneca). Z.K. and M.V.-P. declare honoraria for advisory board\/s (AstraZeneca; Johnson & Johnson). No further conflicts of interest are declared by the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}